| Purpose | (Clinical Focus: This value set focuses on medications used for feminization in transgender women. It captures specific antiandrogen medications and their dosages commonly included in transfeminine hormone replacement therapy (HRT).),(Data Element Scope: This value set defines a specific category of medications within the broader context of gender-affirming hormone therapy. It focuses on antiandrogens, which aim to suppress testosterone production or block its effects.),(Inclusion Criteria: The value set includes all commercially available dosages of spironolactone, a commonly used antiandrogen for feminization:
Oral tablets: 25mg, 50mg, 75mg, 100mg
Oral capsules: 25mg, 50mg, 75mg, 100mg
Oral suspension: 1mg/mL, 2mg/mL, 5mg/mL, 10mg/mL
Additionally, it includes cyproterone acetate, another antiandrogen medication, although specific dosages are not included due to potential variations depending on region and practice.),(Exclusion Criteria: This value set excludes other medications used in transfeminine HRT, such as estrogens and progestins.
It does not capture information about the route of administration (e.g., oral vs. injection) beyond what is included in the concept codes (tablets, capsules, suspension).
It does not include any medications not classified as antiandrogens.) |
FHIR